Inclusion body myositis. Genetics, biomarkers and muscle biopsy

References

• Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23(6):970–972.
   PubMed Web of Science ®Google Scholar
• Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology. 2000;55(9):1385–1387.
   PubMed Web of Science ®Google Scholar
• Wilson FC, Ytterberg SR, St Sauver JL, et al. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008;35(3):445–447.
   PubMed Web of Science ®Google Scholar
• Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70(6):418–424.
   PubMed Web of Science ®Google Scholar
• Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40(4):581–586.
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Amato AA. Inclusion body myositis. Curr Treat Options Neurol. 2000;2(1):7–12.
   PubMedGoogle Scholar
• Ioannis M, Foivos P, Dimitrios K. A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab. Int J Neurosci. 2019;129(3):297–302.
   PubMed Web of Science ®Google Scholar
• Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112(3):727–747.
   PubMed Web of Science ®Google Scholar
• Lindberg C, Persson LI, Bjorkander J, et al. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand. 2009;89(2):123–131.
   Google Scholar
• Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig. 1993;71(5):351–361.
   PubMedGoogle Scholar
• Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992; Sep. 19(9):1385–1389.
   PubMed Web of Science ®Google Scholar
• Greenberg SA. Inclusion body myositis. Continuum (Minneap Minn). 2016;22(6, Muscle and Neuromuscular Junction Disorders):1871–1888.
   PubMedGoogle Scholar
• Badrising UA, Maat-Schieman ML, van Houwelingen JC, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. J Neurol. 2005;252(12):1448–1454. Dec.
   PubMed Web of Science ®Google Scholar
• Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008; 79(9):1056–1060.
   PubMed Web of Science ®Google Scholar
• Larue S, Maisonobe T, Benveniste O, et al. Distal muscle involvement in granulomatous myositis can mimic inclusion body myositis. J Neurol Neurosurg Psychiatry. 2011; 82(6):674–677.
   PubMed Web of Science ®Google Scholar
• Brady S, Squier W, Sewry C, et al. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;4(4):e004552.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Gales T, et al. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol. 1991;48(12):1229–1234.
   PubMedGoogle Scholar
• Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve. 2007; 35(1):17–23.
   PubMed Web of Science ®Google Scholar
• van der Meulen MF, Hoogendijk JE, Moons KG, et al. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord. 2001; 11(5):447–451.
   PubMed Web of Science ®Google Scholar
• Udd B. Distal myopathies-new genetic entities expand diagnostic challenge. Neuromuscul Disord. 2012;22(1):5–12.
   PubMed Web of Science ®Google Scholar
• Nishino I, Carrillo-Carrasco N, Argov Z. GNE myopathy: current update and future therapy. J Neurol Neurosurg Psychiatry. 2015;86(4):385–392.
   PubMed Web of Science ®Google Scholar
• Guinto JB, Ritson GP, Taylor JP, et al. Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. Acta Neuropathol. 2007;114(1):55–61.
   PubMed Web of Science ®Google Scholar
• Roda RH, Schindler AB, Blackstone C, et al. Laing distal myopathy pathologically resembling inclusion body myositis. Ann Clin Transl Neurol. 2014;1(12):1053–1058.
   PubMed Web of Science ®Google Scholar
• Alhammad RM, Liewluck T. Myopathies featuring non-caseating granulomas: Sarcoidosis, inclusion body myositis and an unfolding overlap. Neuromuscul Disord. 2019;29(1):39–47.
   PubMed Web of Science ®Google Scholar
• Amlani A, Choi MY, Tarnopolsky M, et al. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. Front Immunol. 2019; 10:745.
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Amato AA, et al. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016;139(5):1348–1360.
   PubMed Web of Science ®Google Scholar
• Buzkova J, Nikkanen J, Ahola S, et al. Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers. EMBO Mol Med. 2018;10(12):29.
   Web of Science ®Google Scholar
• Dahlbom K, Geijer M, Oldfors A, et al. Association between muscle strength, histopathology, and magnetic resonance imaging in sporadic inclusion body myositis. Acta Neurol Scand. 2019;139(2):177–182.
   PubMed Web of Science ®Google Scholar
• Tasca G, Monforte M, De Fino C, et al. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve. 2015;52(6):956–962. Dec
   PubMed Web of Science ®Google Scholar
• Maetzler W, Reimold M, Schittenhelm J, et al. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. J Neurol Neurosurg Psychiatry. 2011;82(9):1060–1062. Sep
   PubMed Web of Science ®Google Scholar
• Lilleker JB, Hodgson R, Roberts M, et al. [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann Rheum Dis. 2019;78(5):657–662.
   PubMed Web of Science ®Google Scholar
• Rothwell S, Cooper RG, Lundberg IE, et al. Dense genotyping of immunerelated loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. 2016;75(8):1558–1566.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44(3):291–296.
   PubMed Web of Science ®Google Scholar
• Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1∗01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015;47(2):172–179.
   PubMed Web of Science ®Google Scholar
• Gang Q, Bettencourt C, Machado P, et al. Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. Orphanet J Rare Dis. 2014;9(1):88.
   PubMed Web of Science ®Google Scholar
• Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408–418.
   PubMed Web of Science ®Google Scholar
• Weihl CC, Baloh RH, Lee Y, et al. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord. 2015;25(4):289–296.
   PubMed Web of Science ®Google Scholar
• Gang Q, Bettencourt C, Machado PM, et al. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiol Aging. 2016; 47:218.e1–218–218.e9. e9.
   Web of Science ®Google Scholar
• Güttsches AK, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2017;81(2):227–239.
   PubMed Web of Science ®Google Scholar
• Johari M, Arumilli M, Palmio J, et al. Association study reveals novel risk loci for sporadic inclusion body myositis. Eur J Neurol. 2017;24(4):572–577.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Machado PM, Miller A, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med. 2016;8(331):331ra41–331ra41.
   PubMed Web of Science ®Google Scholar
• Rygiel KA, Miller J, Grady JP, et al. Mitochondrial and inflammatory changes in sporadic inclusion body myositis. Neuropathol Appl Neurobiol. 2015;41(3):288–303.
   PubMed Web of Science ®Google Scholar
• Lindgren U, Roos S, Hedberg Oldfors C, et al. Mitochondrial pathology in inclusion body myositis. Neuromuscul Disord. 2015;25(4):281–288.
   PubMed Web of Science ®Google Scholar
• Oldfors A, Larsson NG, Lindberg C, et al. Mitochondrial DNA deletions in inclusion body myositis. Brain. 1993;116(2):325–336.
   PubMed Web of Science ®Google Scholar
• Moslemi A-R, Lindberg C, Oldfors A. Analysis of multiple mitochondrial DNA deletions in inclusion body myositis. Hum Mutat. 1997;10(5):381–386.
   PubMed Web of Science ®Google Scholar
• Rygiel KA, Tuppen HA, Grady JP, et al. Complex mitochondrial DNA rearrangements in individual cells from patients with sporadic inclusion body myositis. Nucleic Acids Res. 2016;44(11):5313–5329.
   PubMed Web of Science ®Google Scholar
• Catalán-García M, Garrabou G, Morén C, et al. Mitochondrial DNA disturbances and deregulated expression of oxidative phosphorylation and mitochondrial fusion proteins in sporadic inclusion body myositis. Clin Sci. 2016;130(19):1741–1751.
   Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58(2):326–326.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58(7):1081–1087.
   PubMed Web of Science ®Google Scholar
• Amato AA, Sivakumar K, Goyal N, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83(24):2239–2246.
   PubMed Web of Science ®Google Scholar
• Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83(5):426–433.
   PubMed Web of Science ®Google Scholar
• Rose MR, 188th ENMC International Workshop. Inclusion body myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscular Disord, 2013;23(12), 1044–1055.
   Google Scholar